Kromek listed on the AIM market in October, 2013 and is a UK company pioneering digital colour imaging for x-rays using cadmium zinc telluride crystals.
14 Jul 2021
Kromek - FY Results - Research & Interview - July 2021
The 19th July 2021 will hopefully ‘go down’ in UK history as the day Covid switched from being a pandemic to an endemic disease. Pent-up demand & acceleration of deferred OEM product launches should also provide a multi-year tailwind for Kromek’s end markets of Medical Imaging, Security Screening, and Homeland Security.
Furthermore, their airborne Covid detector is already making great strides, having commenced field trials in schools, airports (eg Teesside International) and other locations under a £1.25m project with funding from Innovate UK. Plus the device’s efficacy is presently being clinically validated by 3rd party laboratories. Where it is demonstrating “very positive” performance in terms of sensitivity and specificity. In fact, comparable with ‘gold standard’ PCR tests.
Today’s FY21 results saw adjusted FY’21 EBITDA (pre share based payments) come in slightly better than our estimates at -£1.7m (vs ED -£1.9m) on turnover of £10.35m (ED £10.0m). Alongside net cash closing April at £7.4m (split cash +£15.6m, debt £8.2m), after Feb’s £13.0m (gross) fundraise at 15p.
We reiterate our 26p/share valuation based on the strong rebound in demand. Noting the stock at 16p trades on 4.1x FY22 EV/sales vs 5.0x for the sector, yet is set to grow materially faster over the next few years.
Get research on the companies that interest you straight to your inbox
Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.